| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2023
(5 months ago) | |
Glumetza is owned by Santarus Inc.
Glumetza contains Metformin Hydrochloride.
Glumetza has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Glumetza are:
- US8323692
Glumetza was authorised for market use on 03 June, 2005.
Glumetza is available in tablet, extended release;oral dosage forms.
The generics of Glumetza are possible to be released after 23 March, 2025.
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
GLUMETZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic